Lisinopril

Base Information

• Chemical Name: Lisinopril
• CAS No.: 83915-83-7
• Molecular Formula: C21H31O5N3^.2(H2O)
• Molecular Weight: 441.52 .
• Hs Code.: 2933.90
• European Community (EC) Number: 278-488-1,934-016-2
• NSC Number: 758151,751176
• UNII: 7Q3P4BS2FD
• DSSTox Substance ID: DTXSID6040537
• Nikkaji Number: J32.520A
• Wikipedia: Lisinopril
• Wikidata: Q412208
• NCI Thesaurus Code: C29159,C83924
• RXCUI: 29046,1546022
• Pharos Ligand ID: 6Y1P65W348W7
• Metabolomics Workbench ID: 37944
• ChEMBL ID: CHEMBL1237
• Mol file: 83915-83-7.mol

Synonyms:Lisinopril;Lisinopril Maleate (1:1);Lisinopril Sulfate (1:2);Lysinopril;MK-521;Prinivil;Zestril

Chemical Property of Lisinopril

Chemical Property:

• Appearance/Colour: White to off-white crystalline powder
• Vapor Pressure: 1.14E-18mmHg at 25°C
• Melting Point: 148 °C
• Refractive Index: -45 ° (C=1, 0.25mol/L Zinc Acetate Buffer)
• Boiling Point: 666.4 °C at 760 mmHg
• PKA: 2.5, 4.0, 6.7, 10.1(at 25℃)
• Flash Point: 356.9 °C
• PSA: 132.96000
• Density: 1.251 g/cm₃
• LogP: 2.26430
• Storage Temp.: 2-8°C
• Solubility.: H2O: ≥10 mg/mL
• XLogP3: -2.9
• Hydrogen Bond Donor Count: 4
• Hydrogen Bond Acceptor Count: 7
• Rotatable Bond Count: 12
• Exact Mass: 405.22637110
• Heavy Atom Count: 29
• Complexity: 550

Purity/Quality:

99%+ ^*data from raw suppliers

Lisinopril ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xi, Xn
• Hazard Codes: Xi,Xn
• Statements: 20/21/22
• Safety Statements: 22-24/25-36

MSDS Files:

SDS file from LookChem

Useful:

• Drug Classes: Angiotensin-Converting Enzyme Inhibitors
• Canonical SMILES: C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O
• Isomeric SMILES: C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O
• Recent ClinicalTrials: A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
• Recent EU Clinical Trials: The effects of medication induced blood pressure reduction on cerebral hemodynamics in hypertensive frail elderly
• Recent NIPH Clinical Trials: A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
• Description: Lisinopril is an angiotensin converting enzyme inhibitor structurally related to enalaprilat. It is reportedly useful in the management of hypertension and congestive heart failure.
• Uses: An orally active angiotensin-converting enzyme (ACE) inhibitor. S,S,S-Isomer of Lisinopril. These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements. An orally active angiotensin-converting enzyme (ACE) inhibitor. S,S,S-Isomer of Lisinopril
• Clinical Use: Many new ACE inhibitors became available for the treatmentof hypertension following the clinical effectivenessof enalapril. Enalapril is a non–thiol-containing ACE inhibitordevoid of the side effects of rash and loss of thesense of taste characteristic of the thiol-containing compoundcaptopril. With the exception of the phosphoruscontainingfosinopril, these antihypertensive agents havea 2-, like the prototypical drug captopril,are used in the treatment of mild-to-moderate hypertension,either alone or in conjunction with diuretics orcalcium channel blockers.